752222-83-6

GS-6201 (CVT-6883) (4 mg/kg; i.p.; every 12 h for 14 days) significantly reduces IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels^[2].
GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) leads to a significant attenuation of left and right ventricular enlargement and dysfunction at 7 days, which was maintained at 14 days and also at 28 days^[2].
GS-6201 (2 mg/kg; p.o.) treatment shows the C_max, dAUC and t_1/2 are 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively^[1].